Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Hyloris Pharmaceuticals SA ( (DE:52U) ) has provided an update.
Hyloris Pharmaceuticals has announced a positive recommendation from the Independent Data Monitoring Committee (IDMC) to continue the Alenura clinical trial following an interim assessment. Alenura, developed in partnership with Vaneltix Pharma, is being evaluated as a potential first-line treatment for interstitial cystitis/bladder pain syndrome (IC/BPS). The IDMC found no safety concerns and observed promising efficacy signals, allowing the trial to proceed with patient recruitment. This development is significant for Hyloris as it reinforces their confidence in Alenura’s potential and supports their strategy for regulatory discussions and potential market approval.
More about Hyloris Pharmaceuticals SA
Hyloris Pharmaceuticals SA is a specialty biopharma company focused on addressing unmet medical needs by reinventing existing medications. The company operates in the pharmaceutical industry, with a market focus on developing innovative therapies for conditions lacking effective treatments.
YTD Price Performance: -19.33%
Average Trading Volume: 269
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €179.2M
Learn more about 52U stock on TipRanks’ Stock Analysis page.